ABBV250117P162500
- 0.01
- 0.000.00%
AbbVie Newsroom
Raymond James Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $218
BofA Securities Maintains AbbVie(ABBV.US) With Hold Rating, Maintains Target Price $191
Citi Maintains AbbVie(ABBV.US) With Buy Rating, Announces Target Price $205
AbbVie Is Maintained at Buy by Citigroup
AbbVie Analyst Ratings
Express News | Abbvie : Citigroup Cuts Target Price to $205 From $215
Earnings Preview: AbbVie to Report Financial Results Pre-market on January 31
$AbbVie(ABBV.US)$ is scheduled to release its financial results pre-market on January 31 ET. Earnings PreviewAnalysts estimate $AbbVie(ABBV.US)$ to post revenue of USD14.82B for 2024Q4, up 3.61% YOY;
Why AbbVie Stock Popped While the Market Flopped on Monday
AbbVie Builds Momentum With Immunology Growth, Goldman Remains Positive
Goldman Sachs Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $208
FDA Accepts Teva, Alvotech BLAs for Simponi Biosimilars
Do Options Traders Know Something About AbbVie (ABBV) Stock We Don't?
Piper Sandler Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $227
Piper Sandler Sticks to Its Buy Rating for AbbVie (ABBV)
Piper Sandler Adjusts Price Target on AbbVie to $227 From $220, Keeps Overweight Rating
Goldman Sachs Adjusts Price Target on AbbVie to $208 From $205, Keeps Buy Rating
Nvidia, ASML, Tesla, Venture Global, U.S. Steel, AT&T, SoFi, and More Stock Market Movers
Fangzheng Securities: Maintain "Strong Buy" rating for ASCENTAGE-B. The company goes public in the USA, further opening up financing channels in the USA.
Fangzheng Securities released a Research Report stating that on January 24, ASCENTAGE-B (06855) successfully listed on Nasdaq, raising approximately 0.126 billion USD in the US stock market, further opening up financing channels in the USA, gaining new funding support, providing more resources and certainty for subsequent product development, and is expected to accelerate the global commercialization progress of Olverembatinib and the R&D progress of other pipelines. The company's revenue for FY24-26 is expected to be 0.908/0.596/2.63 billion yuan, with year-on-year growth of 303.62%, -34.45%, and 341.68%, respectively, corresponding to FY24.
Apple, AT&T, Tesla, GM, Microsoft, and More Stocks to Watch This Week
Earnings Week Ahead: TSLA, META, AAPL, MSFT, INTC, MA, XOM, LUV and More